Preferred Label : Zeteletinib;
NCIt synonyms : RET Inhibitor DS-5010;
NCIt definition : An orally bioavailable selective inhibitor of wild-type, fusion products and mutated
forms, including gatekeeper mutations, of the proto-oncogene receptor tyrosine kinase
rearranged during transfection (RET), with potential antineoplastic activity. Upon
oral administration, zeteletinib selectively binds to and inhibits the activity of
RET. This results in an inhibition of cell growth of tumors cells that exhibit increased
RET activity. RET overexpression, activating mutations, and fusions result in the
upregulation and/or overactivation of RET tyrosine kinase activity in various cancer
cell types; dysregulation of RET activity plays a key role in the development and
progression of these cancers.;
UNII : EP0P7SHM0U;
CAS number : 2216753-97-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2216753-97-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : BOS-172738; BOS 172738; DS 5010B; CAXM-1190B; DS-5010B;
NCI Metathesaurus CUI : CL937686;
Origin ID : C158093;
UMLS CUI : C5554556;
Semantic type(s)
- concept_is_in_subset
- has_target
